lifestyle.emphas.is

Author: AbbVie Inc.

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease

April 27, 2026
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

April 23, 2026
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

April 22, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

April 13, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

April 13, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through “The Confidence Collective” for Fourth Year

April 8, 2026
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

April 7, 2026
/C O R R E C T I O N — AbbVie/

March 31, 2026
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

March 31, 2026
AbbVie to Host First-Quarter 2026 Earnings Conference Call

March 31, 2026